Boston-based Whoop develops wearable technology for health tracking. Its wrist-worn wearable delivers a 14-day battery life while providing intelligent health guidance across sleep, recovery, strain, fitness and longevity. The health platform includes an FDA-cleared ECG, Healthspan longevity feature, blood pressure insights and Advanced Labs blood biomarker analysis.
Abbott joined in the financing round, along with Mayo Clinic as another big name in healthcare, which brings Whoop to a $10.1 billion valuation. The investment in a wearable health-tracking company closely mirrors Dexcom’s investment in Oura in 2024. The companies went on to integrate Oura’s health-tracking ring with over-the-counter continuous glucose monitor (CGM) technology.
It remains to be seen whether a similar partnership could arise from the investment, as Abbott develops its own health-tracking CGM biosensor technology.
Find out more about Abbott’s medtech strategy during a keynote interview with Abbott EVP and Medical Devices Group President Lisa Earnhardt at DeviceTalks Minnesota, May 4, 2026, at the University of Minnesota’s McNamara Alumni Center. Register here.
Whoop said Abbott joined as a strategic investor, highlighting their shared commitment to empowering people to take control of their health. It hopes to use AI and continuous biometric data to enable a new approach to health, predicting risk, guiding behavior and leading to improvements in real time.
The company plans to use the funds to accelerate its intelligent health platform and prevent disease before it begins. It expects to use proceeds to support further U.S. growth and international expansion.
“Our raise brings together the world’s most sophisticated investors, leading health institutions, and iconic global athletes behind the mission to unlock human performance and healthspan,” said Will Ahmed, founder and CEO of WHOOP. “We are building the personal health platform that people use to improve their health and livelihood.”
